Evotec headquarters in Hamburg. © Evotec SE

Drug discovery CRO Evotec SE announced has entered into a partnership with Inserm, Lille University Hospital and Inserm Transfert to screen new biomarkers and targets in obesity and metabolic diseases.

Award winner Jeroen Verheyen (CEO and co-founder, Semarion, left) with Ignite Award judge Severine Tamas-Lhoustau, Managing Director of Novoptim (Paris, France, right). © Jill Hronek, Director Marketing and Communication at SLAS

UK-based Semarion Ltd. was honoured as the most innovative company in the field of laboratory automation at SLAS Europe 2024 in Barcelona.

Fundus in diabetis retinopathy. © By Shaofeng Hao, Changyan Liu, Na Li, Yanrong Wu, Dongdong Li, Qingyue Gao, Ziyou Yuan, Guanyan Li, Huilin Li, Jianzhou Yang, and Shengfu Fan. - (2022). - wikipedia.org/PLoS One (doi:10.1371/journal.pone.0275983.

US pharma giant Merck Sharp & Dohme (MSD) is decided to acquire London-based ophtalmology expert Eyebiotech Ltd for upt to US$3bn., US$1.7bn in future milestones.

Winning teams of the product award at SLAS Europe 2024 in Barcelona

Swiss Seed Biosciences SA and UK-based Cryologyx Ltd have won the SLAS Europe Product Award 2024 for product developments with transformational potential for the sector.

Eppstein Barr virus infected cells. © CDC

Hornet Therapeutics Ltd will use a US$5m seed financing to launch clinical tests of its IDO1 blocker HTX-201within the next 12 to 18 months to target post-transplant lymphoproliferative disease.

The obesity pipeline mainly consitsts of 1s5-3rd generation incretin combination therapies expected to decrease the BMI by 15, 17 and 22%, respectively. However, oral formulations and other drugs complementing the effect of GLP1 receptor agonists are coming up. © IQVIA

Swiss obesity start up SixPeaks Bio AG has made a good start, announcing a US$30m Series A financing led by Versant Ventures and a US$80m biobucks partnership with AstraZeneca plc.

© ScouserUK - pixabay.com

London-based AI-driven antibody drug discovery specialist LabGenius Ltd has closed a £35m Series B financing round.

Cellugy A/S

Danish industrial biotechnology startup Cellugy raises €4,9m with the ambition to replace petrochemicals in personal care products.

Obesity candidate CT-388, which Genentech added to Roche’s pipeline with the acquisition of Carmot Therapeutics, is at least not a disappointment, according to new trial data.

Possible causes of ME/CFS. By w:Government Accountability Office - https://www.gao.gov/products/gao-22-105666, Public Domain, https://commons.wikimedia.org/w/index.php?curid=132773308

British PrecisionLife Ltd and the Metrodora Institute have announced to launch clinical trials to improve the diagnosis and therapy of long COVID-related ME/CFS.